

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Khan et al.

Patent No.: 6,844,315 B2

Issued: January 18, 2005

For: IMMUNOREGULATOR

Attorney Docket No.: 2183-4799US

VIA ELECTRONIC FILING

November 3, 2008

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT
OFFICE MISTAKES (37 C.F.R. § 1.322)**

Attn.: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is noted that several errors appear in this patent of a typographical nature. These errors are due to mistakes in printing on the part of the U.S. Patent and Trademark Office, and occurred through no fault of the Applicants. A certificate of correction in the form attached hereto is requested.

Please send the Certificate to:

Name: Allen C. Turner
Address: TraskBritt
P.O. Box 2550
Salt Lake City, Utah 84110

Attached hereto is Form PTO/SB/44, which is suitable for printing.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Allen C. Turner", with a long horizontal flourish extending to the right.

Allen C. Turner

Registration No. 33,041

Attorney for Applicants

TRASKBRITT

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: October 30, 2008

ACT/df/ab

Attachments: PTO/SB/44

Document in ProLaw

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,844,315 B2
APPLICATION NO. : 09/821,380
ISSUE DATE : January 18, 2005
INVENTOR(S) : Nisar Ahmed Khan and Robbert Benner

Page 1 of 6

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page:

In ITEM (56) References Cited

below "U.S. PATENT DOCUMENTS" add

--4,977,244 12/1990 Muchmore et al.--
--5,361,992 B1 3/2002 Szkudlinski et al.--
--5,677,275 10/1997 Lunardi-Iskandar et al.--
--5,851,997 12/1998 Harris--
--5,854,004 12/1998 Czernilofsky et al.--
--5,877,148 3/1999 Lunardi-Iskandar et al.--
--5,968,513 10/1999 Gallo et al.--
--5,997,871 12/1999 Gallo et al.--
--6,489,296 12/2002 Grinnell et al.--
--6,583,109 B1 6/2003 Gallo et al.--
--6,596,688 B1 7/2003 Gallo et al.--
--6,620,416 B1 9/2003 Gallo et al.--
--2002/0041871 4/2002 Brudnak--
--2002/0064501 A1 5/2002 Khan et al.--
--2003/0049273 A1 3/2003 Gallo et al.--

below "FOREIGN PATENT DOCUMENTS" add

--DE 3715662 11/1987--
--WO 96/04008 2/1996--
--WO 97/49373 12/1997--
--WO 97/49418 12/1997--
--WO 97/49432 12/1997--
--WO 98/35691 8/1998--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Allen C. Turner
TRASKBRITT
230 South 500 East, Suite 300
Salt Lake City, Utah 84102 USA

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,844,315 B2
APPLICATION NO. : 09/821,380
ISSUE DATE : January 18, 2005
INVENTOR(S) : Nisar Ahmed Khan and Robbert Benner

Page 2 of 6

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page (continued):

In ITEM (56) References Cited

below "FOREIGN PATENT DOCUMENTS" add

--DE 19953339 5/2001--

--EP 1 138 692 A1 10/2001--

--WO 02/085117 0/2002--

--EP 1 300 418 4/2003--

below "OTHER PUBLICATIONS" add

--International Search Report, International Application
No. PCT/NL02/00639, mailed August 4, 2003 (8 pages).--

--Christman et al., Nuclear factor kappaB: a pivotal role
in the systemic inflammatory response syndrome and new
target for therapy, Intens Care Med, 1998, pp. 1131-38,
Vol. 24.--

--Jyonouchi et al., Proinflammatory and regulatory
cytokine production associated with innate and adaptive
immune responses in children with autism spectrum
disorders and developmental regression, J Neuroim., 2001
pp. 170-79, Vol. 120.--

--Kanungo et al., Advanced Maturation of Heteropneustes
Fossilis (Bloch) by Oral Administration of Human
Chorionic Gonadotropin, J. Adv. Zool., 1999, pp.1-5, Vol.
20.--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Allen C. Turner
TRASKBRITT
230 South 500 East, Suite 300
Salt Lake City, Utah 84102 USA

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,844,315 B2
APPLICATION NO. : 09/821,380
ISSUE DATE : January 18, 2005
INVENTOR(S) : Nisar Ahmed Khan and Robbert Benner

Page 3 of 6

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page (continued):
In ITEM (56) References Cited

below "OTHER PUBLICATIONS" add
--Patil, A., et al., "The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study," 87 ACTA NEUROCHIR (WIEN) 76-78 (1987).--
--Rohrig et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 88-89, Vol. 289.--
--Slater, Lewis M., et al. "Decreased Mortality of Murine Graft-Versus-Host Disease by Human Chorionic Gonadatropin," 23(1) TRANSPLANTATION 103-104 (January 1997).--
--Tak et al., NF-kappaB: a key role in inflammatory diseases, J Clin Invest., 2001, pp. 7-11, Vol. 107.--
--Tan et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, Vol. 55.--
--Tovey et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res. 1999, pp. 911-21, Vol. 19.--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Allen C. Turner
TRASKBRITT
230 South 500 East, Suite 300
Salt Lake City, Utah 84102 USA

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,844,315 B2
APPLICATION NO. : 09/821,380
ISSUE DATE : January 18, 2005
INVENTOR(S) : Nisar Ahmed Khan and Robbert Benner

Page 4 of 6

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page (continued):
In ITEM (56) References Cited

below "OTHER PUBLICATIONS" add
--Albini A., et al., "Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG, and somatostatin," 17 CLINICAL & EXPERIMENTAL METASTASIS 739 (1999).--
--Blackwell, Timothy S., et al., The Role of Nuclear factor-kB in Cytokine Gene Regulation," 17 AM. J. RESPIR. Cell MOL. BIOL. 3-9 (1997).--
--Keller, S., et al., Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial cells *in Vitro*," 20(5-6) PLACENTA, page A37 (July 1999).--
--Khan, Nisar A., et al., "Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor," 62(12) HUMAN IMMUNOLOGY 1315-1323 (December 2001).--
--Khan, Nisar A., et al., "Inhibition of Septic Shock in Mice by an Oligopeptide From the β -chain of Human Chorionic Gonadotropin Hormone," 63(1) HUMAN IMMUNOLOGY 1-7 (January 2002).--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Allen C. Turner
TRASKBRITT
230 South 500 East, Suite 300
Salt Lake City, Utah 84102 USA

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,844,315 B2
APPLICATION NO. : 09/821,380
ISSUE DATE : January 18, 2005
INVENTOR(S) : Nisar Ahmed Khan and Robbert Benner

Page 5 of 6

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page (continued):
In ITEM (56) References Cited

below "OTHER PUBLICATIONS" add
--Muchmore et al., Immunoregulatory Properties of Fractions From Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, March 1997, pp. 881-86, Vol. 118, No. 3.--
--Muchmore et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained From Human Pregnancy Urine, Journal of Experimental Medicine, December 1984, pp. 1672-85, Volume 160.--
--Wulczyn, F. Gregory, et al. "The NF-kB/Rel and IκB gene families: mediators of immune responses and inflammation," 74(12) J. MOL. MED. 749-769 (1996).--
--Yamamoto, Y., et al., "Role of the NF-kB Pathway in the Pathogenesis of Human Disease States," 1(3) CURRENT MOLECULAR MEDICINE 287-296 (July 2001).--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Allen C. Turner
TRASKBRITT
230 South 500 East, Suite 300
Salt Lake City, Utah 84102 USA

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,844,315 B2
APPLICATION NO. : 09/821,380
ISSUE DATE : January 18, 2005
INVENTOR(S) : Nisar Ahmed Khan and Robbert Benner

Page 6 of 6

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the specification:

COLUMN 2, LINES 36,37 change "Sj ögrens syndrome" to --Sjögrens syndrome--
COLUMN 13, LINES 12,13 change "Sj ögrens syndrome" to --Sjögrens syndrome--
COLUMN 29, LINE 67, change "(in vivolin vitro)" to --(in vivo/in vitro)--
COLUMN 55, LINES 48,49 change "PCT/NL99/003131" to --PCT/NL99/00313--
COLUMN 60, LINE 37, change "PCT/NL99/003131" to --PCT/NL99/00313--
COLUMN 62, LINE 26, change "PCT/NL99/003131" to --PCT/NL99/00313--
COLUMN 62, LINE 36, change "PCT/NL99/003131" to --PCT/NL99/00313--

In the claims:

CLAIM 3, COLUMN 71, LINE 65, change "tide" to --peptide--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Allen C. Turner
TRASKBRITT
230 South 500 East, Suite 300
Salt Lake City, Utah 84102 USA

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.